Annual results and Q4 2022
Wednesday, February 01, 2023
Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)
Condensed financial report (PDF 0.5 MB)
Download the presentation (PDF 5.1 MB)
Download the podcast (MP3 45 MB)
Read the presentation transcript
Novartis ESG Update Q4 2022 (PDF 0.9 MB)
Key figures1 | Q4 2022 (USD m) |
Q4 2021 (USD m) |
% change (USD/cc) |
---|---|---|---|
Net sales | 12,690 | 13,229 | -4 (cc: 3) |
Operating income | 1,949 | 2,562 | -24 (cc: -14) |
Net income | 1,466 | 16,306 | -91 (cc: -90) |
EPS (USD) | 0.69 | 7.29 | -91 (cc: -89) |
Free cash flow | 3,552 | 3,027 | 17 |
Core |
|||
Operating income | 4,030 | 3,819 | 6 (cc: 15) |
Net income | 3,251 | 3,135 | 4 (cc: 14) |
EPS (USD) | 1.52 | 1.40 | 9 (cc: 19) |
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.